| Patent application number | Description | Published |
|---|
| 20080207494 | Cyclosporin Compositions - Cyclosporin A compositions are disclosed herein comprising an oil and a surfactant. These are useful in the treatment of dry eye disease. | 08-28-2008 |
| 20080213338 | IMPLANT STENT WITH A RETINOID FOR IMPROVED BIOCOMPATIBILITY - An implant device is provided which incorporates a retinoid for improving the biocompatibility of the device in tissue. The device may be bioerodible for the purpose of systemically or locally releasing a therapeutic agent in tissue or it may be a permanent implant which includes a surface treated with a retinoid for increasing the biocompatibility thereof. | 09-04-2008 |
| 20080221524 | NEEDLELESS MICROPROTRUSION ELASTOPLAST SYSTEM - A needleless microprotrusion system for infusion of a medicament into a patient includes a plurality of microprotrusions having a length sufficient to penetrate a stratum corneum of the patient. A chemodenervating agent is disposed for delivery by the microprotrusions and a substrate is provided for supporting the microprotrusions and conforming the microprotrusions to a patient's fossa axilaaris in order to enable uniform penetration of the microprotrusions into the corneum. | 09-11-2008 |
| 20090163550 | RETINOID-CONTAINING SUSTAINED RELEASE INTRAOCULAR IMPLANTS AND RELATED METHODS - Biocompatible intraocular implants include a retinoid component and a biodegradable polymer that is effective to facilitate release of the retinoid component into an eye for an extended period of time. The therapeutic agents of the implants may be associated with a biodegradable polymer matrix, such as a matrix that is substantially free of a polyvinyl alcohol. The implants may be placed in an eye to treat or reduce the occurrence of one or more ocular conditions, such as retinal damage, including glaucoma and proliferative vitreoretinopathy. | 06-25-2009 |
| 20100068244 | STABILIZED BIODEGRADABLE NEUROTOXIN IMPLANTS - Biodegradable neurotoxin implants and methods of making and using such implants are provided. Biodegradable neurotoxin implants include a neurotoxin, a biodegradable polymer component, and an acidity regulating component. The biodegradable polymer component is effective in controlling the release of the neurotoxin from the implant when the implant is located in a patient's body. The acidity regulating component is effective in maintaining a pH of the implant in a desired range that may be effective in stabilizing the neurotoxin as the implant biodegrades when the implant is located in a patient's body. In one embodiment, an implant includes a botulinum toxin, a biodegradable polymer, and either monomers from which a biodegradable polymer is derived or oligomers including monomeric units substantially identical to a monomer from which a biodegradable polymer is derived, or a combination of such monomers and oligomers. The oligomers and biodegradable polymer may be derived from a single type of monomer. The implants disclosed herein may be administered to a human or animal patient in which a therapeutic effect is desired for prolonged periods of time. | 03-18-2010 |
| 20100222587 | COMPOSITIONS AND METHODS FOR THE INTRAOCULAR TRANSPORT OF THERAPEUTIC AGENTS - Membrane transporter-targeted therapeutic agents and methods of making and using the same. | 09-02-2010 |
| 20100331430 | PHARMACEUTICAL COMPOSITIONS CONTAINING PROPIONIC PRESERVATIVE COMPONENTS - The invention provides ophthalmic compositions preserved using propionic preservative components alone or in combination with at least one additional preservative. In particular, an improvement in anti-microbial activity against bacteria is seen in addition to activity specific to fungal organisms and/or mold. | 12-30-2010 |
| 20110076318 | RETINOID-CONTAINING SUSTAINED RELEASE INTRAOCULAR IMPLANTS AND RELATED MATTERS - Biocompatible intraocular implants include a retinoid component and a biodegradable polymer that is effective to facilitate release of the retinoid component into an eye for an extended period of time. The therapeutic agents of the implants may be associated with a biodegradable polymer matrix, such as a matrix that is substantially free of a polyvinyl alcohol. The implants may be placed in an eye to treat or reduce the occurrence of one or more ocular conditions, such as retinal damage, including glaucoma and proliferative vitreoretinopathy. | 03-31-2011 |
